‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ‒ Phase IIb clinical trial was a prospective, ...
Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence A positive baseline immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results